Navigation Links
Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
Date:1/23/2008

ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Human Genome Sciences Inc. (Nasdaq: HGSI) announced today that it will modify the dosing in one arm of each of its ACHIEVE clinical trials of Albuferon(R) (albinterferon alfa-2b) for chronic hepatitis C. Patients in the Phase 3 trials who have been receiving the 1200-mcg dose will now receive a 900-mcg dose. The change is based on recommendations made by the studies' independent Data Monitoring Committee (DMC). HGS continues to expect to have all Phase 3 data available by spring 2009 to support the filing of global marketing authorization applications by fall 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"For some time we have viewed the 900-mcg dose administered every two weeks as the most likely marketed dose of Albuferon," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "The 900-mcg dose demonstrated comparable efficacy and safety to Pegasys in Phase 2 - with half the injections, improvements in quality of life and fewer missed days of work during treatment. We continue to believe that Albuferon could become the market-leading interferon for the treatment of hepatitis C if Phase 2 900-mcg results are confirmed in Phase 3."

Consistent with its charter, the DMC routinely reviews all adverse events for each treatment group. Serious pulmonary adverse events, while expected and rare during interferon therapy, were higher in the treatment group receiving 1200-mcg Albuferon administered every two weeks. The DMC did not express any safety concerns about the 900-mcg dose of Albuferon. Based on the DMC's review and conclusions, the patients receiving a 12
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Reports Successful Cloning of Human Embryo Using Adult DNA
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
6. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
7. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
10. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
11. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., RANCHO CORDOVA, Calif., Nov. 25 /PRNewswire/ -...American Pacific Corporation (Nasdaq: APFC ) anno...ponsibility and Sustainability Award at the Annual...California Manufacturers and Technology Associatio... (IEA) and the Chemical Industry Council of Califo...
(Date:11/25/2009)... , HARBIN, China, Nov. 25 /PRNewswire-As...na Sky One Medical" or "the Company") (Nasdaq: CS...mpany developing and producing,over-the-counter dr...ay,announced that the Company recently passed the ...maceutical and Biological Products ("ICPBP") exami...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Report...port is available in its catalogue: ,, Mammog..., http://www.reportlinker.com/p0164330/Mammogra...,, Rising incidence of breast cancer in industr...al factor influencing growth in the mammography ma...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8VBI awarded 2427 million from NIH to support infectious disease research 10266 1VBI awarded 2427 million from NIH to support infectious disease research 10266 2VBI awarded 2427 million from NIH to support infectious disease research 10266 3VBI awarded 2427 million from NIH to support infectious disease research 10266 4Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 1Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 2Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6
...ieved at Least 75 Percent Improvement in Psoriasis...sing Groups, More,Than Half Achieved 90 Percent Im...wire-FirstCall/ -- New,Phase II study results show...ced psoriasis symptoms significantly in the majori...0 patients with,moderate to severe psoriasis achie...
...nd, 4th May 2007 - CeNeS Pharmaceuticals plc,(LSE:...ny, notes,the publication of an independent study ...its Phase II NMDA antagonist, CNS 5161. CeNeS,is d...uropathic,pain. The independent study builds on th...5161. , In the study reported in ,Synapse, Dr Ana...
Other Medicine Technology:Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:11/27/2009).... 27 Preventing disease...tunately every year, new vaccines are being added ...es boost immunity for the same period of time? And...ed to keep immunity strong? ,, In this month,... Academy of Pediatrics, Michael Pichichero MD, Dir...
(Date:11/27/2009)...re Holdings has announced that it has become a nat...the largest nonprofit organizations dedicated to a... Delray Beach, FL (Vocus) N...: XCHO), a company specializing in the marketing a...ucts, has announced today that is has become a nat...
(Date:11/27/2009)...TLE, Nov. 27 Allrecipes.com , t...ksgiving traffic numbers, with more than 2.8 milli... a clear picture of what was served on the biggest...g meal in 2009 weighed in at 2,225 calories per se.... According to the Allrecipes site, Sweet Potato ...
(Date:11/27/2009)...list manufacturers who use medical load cells at t...dollars by bringing in technology partner Flintec ... pro-active medical manufacturers are calling in F...heir projects, ensuring that progress will not be ...ially outdated technology. , ...
(Date:11/26/2009)...ov. 27 The diabetes population in ... 25 years and annual medical spending on the disea...billion today, according to a study published in t...l Changing Diabetes ® Program (NCDP), a prog...a team from the University of Chicago. ,, Accor...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
... study of patients, doctors and family members sug...lls. When someone has a terminal illness, they may...dical procedures in a 'living will'. For example t...e death, may wish every possible measure to be tak...
...ew research from Albert Einstein College of Medic...ol that may help them predict who will develop a f... Albert Einstein College of Medicine finds the pre...a. Gait disorders are increasingly common wit...
... latest study researchers have observed that docto...blood pressure and other cardiac risk factors in e...pital, Georgia have carried out a population surve...gin have the lowest risk of heart disease, and the...
...esearchers in a study working with animals say the...rning. Although the research is early, they say it...ory and learning disorders. Researchers say previo...memory formation. They say this study provides a d...
...he latest study researchers proposed that large do...treatment for prostate cancer. Researchers say ten...minister vitamins and minerals,// and use untested...ng their health but inadvertently endanger their h...
...ve built a new model of the airway, which shows an...cations. In sleep apnoea, the upper airway tends t...the free flow of air.// This actually causes breat...prone to sleep apnoea than women and researchers i...
Other Medicine News:
IEC CL30 Centrifuge
HIV 1 /2 STAT-PAK Assay
REAL-Time Continuous Glucose Monitoring
Platelet Aggregation Profiler Model PAP-8E
Medicine Products: